Equities Analysts Issue Forecasts for Alumis FY2025 Earnings

Alumis Inc. (NASDAQ:ALMS) – Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Alumis in a research report issued on Thursday, March 20th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($5.36) per share for the year, down from their prior forecast of ($4.13). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

Other equities research analysts have also issued research reports about the company. Oppenheimer started coverage on Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $15.00 price target (down from $19.00) on shares of Alumis in a report on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $26.00.

Alumis Stock Up 5.8 %

NASDAQ ALMS opened at $4.00 on Monday. The firm’s fifty day moving average price is $5.55 and its two-hundred day moving average price is $8.43. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53.

Hedge Funds Weigh In On Alumis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in Alumis during the 3rd quarter valued at approximately $27,000. Wells Fargo & Company MN boosted its stake in shares of Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after purchasing an additional 3,823 shares during the last quarter. Northern Trust Corp increased its position in shares of Alumis by 4.3% during the fourth quarter. Northern Trust Corp now owns 111,326 shares of the company’s stock worth $875,000 after buying an additional 4,587 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Alumis by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock worth $891,000 after buying an additional 4,808 shares during the last quarter. Finally, Barclays PLC lifted its holdings in Alumis by 33.9% in the fourth quarter. Barclays PLC now owns 24,581 shares of the company’s stock valued at $193,000 after buying an additional 6,221 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.